Latest News and Press Releases

Data will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026 COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio...

New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune responseThe results reinforce that Evaxion’s pioneering...

Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The trial has already yielded encouraging one- and two-year data...

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology™ platformEVX-04 is a therapeutic cancer vaccine candidate...

75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation...

Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing...

New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting The data will be the latest of many...

Evaxion’s AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patientsFindings further confirm and validate the precision and...